CNC241213C55000
- 5.06
- +3.83+311.38%
Centene Newsroom
Neurocrine Wins FDA Nod for CAH Therapy
Weekly Buzz: Tech stocks hit high scores on ominous day
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Centene Stock Undervalued After Clarity Emerges on Post-ACA Subsidy Expiration, UBS Says
Unusual Options Activity: PINS, BRKR and Others Attract Market Bets, PINS V/OI Ratio Reaches 892.9
Centene Shares Are Trading Higher After the UBS Upgraded the Stock From Neutral to Buy and Raised Its Price Target From $79 to $80. Also, Barclays Maintained an Overweight Rating on the Stock and Raised Its Price Target From $91 to $93.
Express News | Centene Shares Are Trading Higher After the UBS Upgraded the Stock From Neutral to Buy and Raised Its Price Target From $79 to $80. Also, Barclays Maintained an Overweight Rating on the Stock and Raised Its Price Target From $91 to $93
Market Mixed on Friday the 13th | Livestock
Centene Is Maintained at Buy by Truist Securities
Centene Price Target Raised to $93.00/Share From $91.00 by Barclays
Express News | Barclays Maintains Overweight on Centene, Raises Price Target to $93
Centene Unveils Its 2025 Guidance, Reaffirms 2024 Outlook
This PayPal Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Centene Price Target Cut to $85.00/Share From $95.00 by Oppenheimer
Centene Is Maintained at Outperform by Oppenheimer
Wells Fargo Maintains Centene(CNC.US) With Buy Rating, Raises Target Price to $76
Oppenheimer Maintains Centene(CNC.US) With Buy Rating, Cuts Target Price to $85
A Quick Look at Today's Ratings for Centene(CNC.US), With a Forecast Between $73 to $93
Oppenheimer Reaffirms Their Buy Rating on Centene (CNC)
Analysts Are Bullish on These Healthcare Stocks: Medios AG (MEDOF), Centene (CNC)